

Acula Technology Corp.

Stock Code : 3434

INVESTOR CONFERENCE

by S.S. Jian / Vice President

2024-12-12

Disclaimer

The content of this briefing may contain, but not limited to, future prospects, forecasts, estimates and other anticipatory descriptions. These statements are made based on the Company's operating beliefs and its current view of the future. These opinions may be affected by internal and external risks and uncertainties, which may cause the actual results to be significantly different from the stated contents.

Any explanations made in this briefing are only applicable on the date of statement. Investors should have their own judgment and should not rely too much on the explanations. For these instructions, except for the regulations, if there are any changes or adjustments in the future, the company is not responsible for reminding or updating them at any time. The cautionary statement stated on this page applies to all related statements contained in this presentation.

1. Company Overview

- **Established:** May 05, 1993
- **Company Listed:** Jan 28, 2008
- **Chairman and General Manager:** Louis Jean
- **Capital:** 280.3 Million NTD
- **Main Products:** Surveillance Application Series, Industrial Application Series, and Healthcare Application Series
- **Quality Certified:** ISO 9001 / 14001 / 13485 / QMS
- **Address:** 11, Alley 21, Lane 20, Dashing Rd., Luchu Dist.,
Taoyuan City 338024, Taiwan
- **Employees :** 112 persons

2. Recap of Recent Milestones

- **2016. 12 – ISO 13485 : 2003 Certified**
 - Mass-produced healthcare application series – clinical use
- **2018. 11 – Pharmacist Manufacturing License**
 - Medical Device License (Class 1)
- **2019. 02 – ISO 13485 : 2016 Certified**
 - 2019. 09 – Medical Device License (Class 2)
 - 2019. 11 – Medical Device GMP Certificate
- **2022. 09 – QMS Certified**
- **2024. 06 – FDA 510(k) Premarket Notification of PGY (Display, Diagnostic Radiology)**

3. Business Philosophy


- ◆ **Create value for customers, shareholders, employees and suppliers**
- ◆ **Specialize in ODM/ OEM business**
- ◆ **Integrity, Enthusiasm, Professionalism, Innovation**

4. Operational Overview (1): Income Statement

Unit: NTD K

	2023 Q1-Q3	%	2024 Q1-Q3	%
4110 Net Revenue	498,259	100%	546,821	100%
5110 Operating costs	414,137	83%	434,626	79.5%
5900 Gross Profit	84,122	17%	112,195	20.5%
6000 Operating expenses	(71,087)	-14%	(76,154)	-13.9%
6900 Operating income	13,035	3%	36,041	6.6%
7000 Non-operating items	9,905	2%	8,570	1.6%
7900 Net income before tax	22,940	5%	44,611	8.2%
7951 Tax expense	(4,820)	-1%	(9,283)	-1.7%
Net income	18,120	4%	35,328	6.5%
EPS	0.65		1.26	


4. Operational Overview (2): EPS since 2021



5. Revenue (1) by Area


Revenue by Area

■ USA ■ EU ■ UK ■ JAPAN ■ TAIWAN



5. Revenue (2) by Application

Revenue by Application ■ CCTV ■ Industrial ■ Others



6. 4Q24 Guidance

■ R&D

- 2 CCTV models for low vision application enter mass production
- Medical grade 23.8" display proposal for medical equipment
- 23.8" clinical review (plus) medical display development
- New generation CCTV for low vision application development
- Next generation CCTV network camera development
- Portable diagnostic display development evaluation

■ Business

- Expect revenue to be grown compared with 4Q23
- Expect gross profit margin almost equal to 3Q24

7. Recap of Recent Major Events

- The board of directors approved the issuance of CB (Convertible Bond)
- Complete ISO 13485 certificate renewal on 12/6

8. Company Vision

* ACULA Vision *

SECURE LIFE

IMPROVE LIFE

ENJOY LIFE

* ACULA Goal *

A Leading Video Solution Provider



Company website: <http://www.acula.com>

<http://www.acula.com.tw>

Spokesperson: S.S. Jian / Vice President

ssjian@acula.com.tw

Acting Spokesperson: Michelle Chen/ Vice President

michellechen@acula.com.tw

Stock Affairs Contact: Sunny Chung/ Manager

sunnychung@acula.com.tw